CN113728099A - Crispr/cas融合蛋白和系统 - Google Patents

Crispr/cas融合蛋白和系统 Download PDF

Info

Publication number
CN113728099A
CN113728099A CN202080029346.8A CN202080029346A CN113728099A CN 113728099 A CN113728099 A CN 113728099A CN 202080029346 A CN202080029346 A CN 202080029346A CN 113728099 A CN113728099 A CN 113728099A
Authority
CN
China
Prior art keywords
protein
cells
sequence
fusion protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080029346.8A
Other languages
English (en)
Chinese (zh)
Inventor
陈福强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Aldrich Co LLC
Original Assignee
Sigma Aldrich Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co LLC filed Critical Sigma Aldrich Co LLC
Publication of CN113728099A publication Critical patent/CN113728099A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202080029346.8A 2019-02-15 2020-02-13 Crispr/cas融合蛋白和系统 Pending CN113728099A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806708P 2019-02-15 2019-02-15
US62/806708 2019-02-15
PCT/US2020/018145 WO2020168102A1 (en) 2019-02-15 2020-02-13 Crispr/cas fusion proteins and systems

Publications (1)

Publication Number Publication Date
CN113728099A true CN113728099A (zh) 2021-11-30

Family

ID=70166116

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080029346.8A Pending CN113728099A (zh) 2019-02-15 2020-02-13 Crispr/cas融合蛋白和系统

Country Status (11)

Country Link
US (3) US10947517B2 (https=)
EP (1) EP3924475A1 (https=)
JP (2) JP2022520104A (https=)
KR (1) KR20210139271A (https=)
CN (1) CN113728099A (https=)
AU (2) AU2020221274B2 (https=)
BR (1) BR112021016019A2 (https=)
CA (1) CA3129835A1 (https=)
IL (1) IL285300A (https=)
SG (1) SG11202108812SA (https=)
WO (1) WO2020168102A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116063546A (zh) * 2021-10-29 2023-05-05 深圳先进技术研究院 一种基于共振能量转移的全遗传编码nad+蛋白探针及其制备方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10947517B2 (en) 2019-02-15 2021-03-16 Sigma-Aldrich Co. Llc CRISPR/Cas fusion proteins and systems
AU2022343268A1 (en) * 2021-09-08 2024-03-28 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
WO2023163806A1 (en) * 2022-02-22 2023-08-31 Massachusetts Institute Of Technology Engineered nucleases and methods of use thereof
EP4489772A4 (en) * 2022-03-08 2026-03-25 Univ Wake Forest Health Sciences EUKARYOTIC GENE EDITING COMPOSITIONS, SYSTEMS AND METHODS
WO2025221793A1 (en) * 2024-04-16 2025-10-23 Monsanto Technology Llc Modified cas proteins for nuclear localization and editing activity in plants

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186686A2 (en) * 2013-05-17 2014-11-20 Two Blades Foundation Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
US20160136293A1 (en) * 2013-06-11 2016-05-19 Portage Pharmaceuticals Ltd. Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
US20160355797A1 (en) * 2013-12-12 2016-12-08 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
WO2018071868A1 (en) * 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
CN107949400A (zh) * 2015-06-24 2018-04-20 西格马-奥尔德里奇有限责任公司 细胞周期依赖性基因组调控和修饰
CN108913676A (zh) * 2012-12-06 2018-11-30 西格马-奥尔德里奇有限责任公司 基于crispr的基因组修饰和调控

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005010A (es) 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
EP3122880B1 (en) 2014-03-26 2021-05-05 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
EP3201340B1 (en) 2014-10-01 2020-12-02 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
WO2017131150A1 (ja) * 2016-01-29 2017-08-03 国立大学法人東京大学 Ｃａｓ９－ｇＲＮＡ複合体の製造方法、Ｃａｓ９－ｇＲＮＡ複合体の細胞核内への導入方法、及び細胞内における標的遺伝子の改変方法
WO2017173004A1 (en) * 2016-03-30 2017-10-05 Mikuni Takayasu A method for in vivo precise genome editing
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
CN107579793A (zh) * 2016-07-04 2018-01-12 中兴通讯股份有限公司 一种通信网络设备间时间同步的优化方法、装置及设备
CN110214183A (zh) * 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
BR112019012155A2 (pt) 2016-12-14 2019-11-12 Wageningen Universiteit uso de pelo menos uma molécula-guia de rna e uma proteína cas, método de ligação, clivagem, marcação ou modificação de um polinucleotídeo alvo de fita dupla, célula transformada, e, complexo de nucleoproteína
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
SG11202000840YA (en) 2017-07-31 2020-02-27 Reflection Biotechnologies Ltd Cellular models of and therapies for ocular diseases
US11071791B2 (en) * 2018-01-26 2021-07-27 Wisconsin Alumni Research Foundation Vector for gene silencing and replacement and methods of use thereof
KR102465067B1 (ko) 2018-02-15 2022-11-10 시그마-알드리치 컴퍼니., 엘엘씨 진핵 게놈 변형을 위한 조작된 cas9 시스템
WO2019178427A1 (en) * 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
US10947517B2 (en) 2019-02-15 2021-03-16 Sigma-Aldrich Co. Llc CRISPR/Cas fusion proteins and systems

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108913676A (zh) * 2012-12-06 2018-11-30 西格马-奥尔德里奇有限责任公司 基于crispr的基因组修饰和调控
WO2014186686A2 (en) * 2013-05-17 2014-11-20 Two Blades Foundation Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
US20160136293A1 (en) * 2013-06-11 2016-05-19 Portage Pharmaceuticals Ltd. Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
US20160355797A1 (en) * 2013-12-12 2016-12-08 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
CN107949400A (zh) * 2015-06-24 2018-04-20 西格马-奥尔德里奇有限责任公司 细胞周期依赖性基因组调控和修饰
WO2018071868A1 (en) * 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PEI ZHAO ET AL: "One-step homozygosity in precise gene editing by an improved CRISPR/Cas9 system", 《CELL RESEARCH》, 8 April 2016 (2016-04-08), pages 633 *
姚文兵 等: "《生物技术制药概论》", 31 August 2015, 中国医药科技出版社, pages: 75 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116063546A (zh) * 2021-10-29 2023-05-05 深圳先进技术研究院 一种基于共振能量转移的全遗传编码nad+蛋白探针及其制备方法和应用

Also Published As

Publication number Publication date
WO2020168102A1 (en) 2020-08-20
US10947517B2 (en) 2021-03-16
IL285300A (en) 2021-09-30
US20210163910A1 (en) 2021-06-03
BR112021016019A2 (pt) 2021-10-05
US20230287377A1 (en) 2023-09-14
US11965184B2 (en) 2024-04-23
AU2020221274A1 (en) 2021-08-26
CA3129835A1 (en) 2020-08-20
US20200263155A1 (en) 2020-08-20
AU2020221274B2 (en) 2024-02-08
JP2022520104A (ja) 2022-03-28
SG11202108812SA (en) 2021-09-29
AU2024202275A1 (en) 2024-05-23
JP2023156365A (ja) 2023-10-24
EP3924475A1 (en) 2021-12-22
KR20210139271A (ko) 2021-11-22

Similar Documents

Publication Publication Date Title
AU2021200636B2 (en) Using programmable dna binding proteins to enhance targeted genome modification
JP7559005B2 (ja) 真核ゲノム修飾のための操作されたＣａｓ９システム
JP7469285B2 (ja) 標的化されたゲノム修飾を増強するためのヌクレオソーム相互作用タンパク質ドメインの使用
US20230287377A1 (en) Crispr/cas fusion proteins and systems
JP2020530992A (ja) Ｃｒｉｓｐｒ／ｃａｓアクチベーターシステムのための合成ガイドｒｎａ
JP7629673B2 (ja) ゲノム改変のための高忠実度ＳｐＣａｓ９ヌクレアーゼ
HK40075530A (en) High fidelity spcas9 nucleases for genome modification
HK40040051A (en) Engineered cas9 systems for eukaryotic genome modification
HK40023852A (en) Synthetic guide rna for crispr/cas activator systems
HK40040051B (zh) 用於真核基因组修饰的改造的cas9系统

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211130

WD01 Invention patent application deemed withdrawn after publication